

# Baseline Characteristics of Patients With Overactive Bladder Receiving Navigated or Routine Care Identified From a US National Retrospective Database Study

Ekene Enemchukwu,<sup>1</sup> Jennifer Miles-Thomas,<sup>2</sup> Nitya Abraham,<sup>3</sup> Lei Luo,<sup>4</sup> Diane K. Newman,<sup>5</sup> Mariana Nelson,<sup>6</sup> Raveen Syan<sup>7</sup>

<sup>1</sup>Stanford Multidisciplinary Pelvic Health Center, Stanford Health Care, Redwood City, CA, USA; <sup>2</sup>Eastern Virginia Medical School, The Devine-Jordan Center for Reconstructive Surgery and Pelvic Health, Virginia Beach, VA, USA; <sup>3</sup>Montefiore Medical Center, Bronx, NY, USA; <sup>4</sup>AbbVie, Madison, NJ, USA; <sup>5</sup>Perelman School of Medicine, University of Pennsylvania, Penn Center for Continence and Pelvic Health, Division of Urology, Philadelphia, PA, USA; <sup>6</sup>AbbVie, Lake Bluff, IL, USA; <sup>7</sup>University of Miami, Miller School of Medicine, Miami, FL, USA

## OBJECTIVE

To describe real-world demographics and geographic characteristics of patients with overactive bladder (OAB) who received navigated care compared with those who did not receive navigated care

## CONCLUSIONS



Among patients with OAB in this analysis, the vast majority (>80%) were not assigned a nurse navigator and, of those who were, rates were highest among women identified in the database as Black, Asian, or White



Patients with OAB on Medicaid or Medicare were also more likely to receive navigated care versus those with other insurance types; rates of navigated care were highest in Philadelphia and Chicago Medicare regions

For additional information or to obtain a PDF of this poster

Scan QR code or use the following link to download an electronic version of this presentation and other AbbVie 2022 SUNA scientific presentations:

<https://abbvie1.outsystemsenterprise.com/GMAEventPublications/Assets.aspx?ConferenceId=444>

QR code expiration: September 26, 2022

To submit a medical question, please visit [www.abbviemedinfo.com](http://www.abbviemedinfo.com)



AbbVie and the authors thank the participants, study sites, and investigators who participated in this clinical trial. AbbVie funded this trial and participated in the trial design, research, analysis, data collection, interpretation of data, and the review and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Palsson Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA. Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors. Nitya Abraham participated in a speaker's bureau for Urovent (March-October 2021). Ekene Enemchukwu served on a research advisory board for Urovent and Andrius. Lei Luo and Mariana Nelson are employees of AbbVie and may hold AbbVie stock. Jennifer Miles-Thomas participated in a speaker's bureau for AbbVie and Actelion and was a consultant for AbbVie. Diane K. Newman has served as a consultant for Urovent and as an editor for Digital Science Press, and has received grant/research support from the National Institutes of Health. Raveen Syan has no conflicts of interest to disclose. This data was originally presented at the 2022 American Urologic Society (AUGS) and International Urogynecological Association (IUGA) Scientific Meeting.

### References

- Urology Care Foundation. Overactive Bladder (OAB): Symptoms, Diagnosis & Treatment. [https://www.urologyhealth.org/urology-a-to-z/overactive-bladder-\(oab\)](https://www.urologyhealth.org/urology-a-to-z/overactive-bladder-(oab)). Accessed 01/11/2022.
- Shayya FT, et al. *Am J Managed Care*. 2005;11(4 Suppl):S121-S129.
- Wagdy A, et al. *BJU Int*. 2012;110(11):1767-1774.
- Moskowitz D, et al. *J Urol*. 2016;195:789-794.
- Syan R, et al. Identifying navigator impact on utilization of onabotulinumtoxinA as a 3rd line treatment in overactive bladder: A retrospective database study in the United States. Abstract presented at: 2022 Society of Uroynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Winter Meeting, Feb. 22-26, 2022, San Diego, CA.


## INTRODUCTION

### Background

- Overactive bladder (OAB) is a highly prevalent condition, affecting as many as 30% of men and 40% of women in the United States<sup>1</sup>
- Although effective interventions are available, OAB often remains undertreated
  - First-line behavioral interventions and second-line oral medications are insufficient and may be intolerable for many patients, and persistence with oral medication is low<sup>2,3</sup>
  - However, fewer than 5% of patients with OAB overall and 10% of those treated by urology providers progress to third-line treatment with onabotulinumtoxinA injection, percutaneous tibial nerve stimulation, or sacral nerve stimulation<sup>4</sup>
- Navigation of care by a dedicated professional can help guide patients through the OAB clinical pathway
- Navigator care can also lead to increased advancement and adherence to third-line treatment options<sup>5</sup>
- Limited information exists regarding real-world demographics of OAB patients and treatment, including access to navigation of care

## RESULTS


### Patient Demographics: Gender



<sup>a</sup>Study sample included 1 patient with unknown gender.  
<sup>b</sup>Navigated patients vs non-navigated patients, based on a two-sided Pearson's chi-square test.

- A greater proportion of women than men received navigated care (17.4% of women vs 5.8% of men, *P*<0.001)

### Patient Demographics: Race<sup>a</sup>




<sup>a</sup>Racial group names consistent with database entries.


- The highest proportion of patients receiving navigated care were Black (18.2%)

## METHODS

- A random set of patients with OAB were retrospectively identified using ICD-9-CM, ICD-10-CM, and procedure codes from the Precision Point Specialty Analytics Portal for OAB database, which contains electronic medical record data for more than 90 community-based urology practices in the United States that provide care to over 2.4 million patients with OAB




### Patient Demographics: Insurance Type



- The highest proportions of patients receiving navigated care were those on Medicaid and Medicare

### Geographic Characteristics



- The highest proportions of patients receiving navigated care were in Medicare regions 3 (Philadelphia) and 5 (Chicago)